Podcasts about jnj

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Ministro del Interior sobre la violencia criminal en el país: “Extrañamos a nuestros delincuentes". - JNJ propone suspender a la fiscal de la nación Delia Espinoza por seis meses. - Gestión de López Aliaga contrató por más de S/7,2 millones a militantes de Renovación Popular. - Las mentiras de Willax sobre los pueblos indígenas y los Piaci. - TC evaluará en última instancia habeas corpus de Santiváñez para que se ordene a Fiscalía el cese de sus pretensiones de privarlo de su libertad. - Condenan a agresor del exfiscal Avelino Guillén en el año 2021. - Martín Vizcarra reveló cómo fue su encuentro con Pedro Castillo en Barbadillo. - Videopodcast: La salida de la Corte IDH y la desprotección a jueces, fiscales y pueblos indígenas. - Exclusivo: César Acuña y los vehículos comprados para la seguridad ciudadana que no se usan.

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.If you've ever wondered whether you can truly live off dividends, this video breaks it all down in plain English. We're taking a deep dive into dividend investing strategies, looking at what works, what doesn't, and why chasing high yields can be riskier than it looks. You'll discover how some investors with less than $500,000 are already living off dividends, why Johnson & Johnson's 2.9% yield is both attractive and limited, and how a stock's price growth can often dwarf its dividend payouts.The video explores the real math behind dividend yields, capital appreciation, and how compounding growth changes the game. You'll see examples like JNJ up 24% year to date, covered call ETFs generating steady income, and REITs offering additional streams of cash flow. But there's also a warning—stocks like UPS and Pfizer may boast 6% to 7% dividends, but if the share price drops 30%, that income doesn't look so appealing. The truth is, focusing only on yield often means missing the bigger picture.We also compare different approaches: blue chip dividend stocks, Treasury ETFs with near-zero risk, covered call ETFs like QYLD and JEPI, and even ultra-high-yield funds like YieldMax. Each comes with trade-offs. Some offer consistency but limited growth, others carry massive risk despite eye-popping yields. By the end, you'll understand how to balance income with growth, and why protecting your principal is just as important as generating cash flow.A big focus here is taxes and classifications. Dividends aren't all equal—some are qualified and taxed at lower capital gains rates, while others are ordinary income taxed at your highest bracket. Covered call ETFs often include return of capital, which can defer taxes but also lower your cost basis. These details matter if you're planning to retire early or live off passive income before traditional retirement age.This isn't just theory. The strategies covered include real-world examples of dividend stocks, REITs, ETFs, and funds being used right now. You'll learn why “all stocks are bad but sometimes they act right” and how to recognize those moments with tools like the OVTLYR trend template. More importantly, you'll see why sitting in cash at 4% APY might sometimes beat chasing risky yields.Whether you're aiming for financial freedom, retirement income, or just smarter portfolio management, this video shows how dividend strategies really play out in practice. The goal isn't just collecting drips of cash—it's capturing the flood of opportunity when growth and income align.➡️ Learn why dividend investing isn't a one-size-fits-all approach➡️ See how to spot traps in “too good to be true” high yields➡️ Compare low-risk vs. high-yield income strategies➡️ Understand the tax implications of dividends and ROC➡️ Use OVTLYR's behavioral analytics to know when to hold and when to move to cashGain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Piden al Gobierno declarar emergencia sanitaria en Daten del Marañón ante epidemia de Tosferina. - Comisión multisectorial decide hoy sobre la creación de la Reserva Indígena Yavarí Mirim, en Loreto. - Hoy se realizará un nuevo Planton “Hasta que la justicia se haga costumbre”. - Primer ministro le responde a fiscal de la nación: “No quiere gastar o no sabe gastar”. - Dina Boluarte firma convenio para construcción de El Frontón. - Martín Vizcarra sale en libertad: Poder Judicial ordena su excarcelación. - Betssy Chávez saldrá en libertad: Tribunal Constitucional ordenó su excarcelación inmediata. - Congreso rechaza pedido de fiscal la nación para reactivar denuncias. - Exclusiva: La proyección de los votos en el proceso de vacancia contra Gino Ríos en la JNJ.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Caso Saweto: embajadas de Alemania, Canada, Noruega y Reino Unido destacan sentencia del PJ contra asesinos de defensores ambientales. - Asesinan a diplomático de la embajada de Indonesia en los exteriores de su residencia en Lince. - Congreso impulsa 26 proyectos para hacer una reforma judicial a su medida. - Juan José Santiváñez: "Parte del Ministerio Público conforma una organización criminal". - Caso Gino Ríos: JNJ realizará audiencia el próximo jueves para evaluar pedidos de vacancia. - Presidenta del TC en línea con discurso del Gobierno: cuestiona allanamiento a Nicanor Boluarte. - Eduardo Arana brinda entrevista a Diego Acuña luego que acompañara a la delegación de la PCM a Santa Rosa de Loreto - The Economist tilda de “caricaturesco” a Rafael López Aliaga y critica su gestión en la MML: “La deuda de Lima ha aumentado”. - Manuel Merino y Ollanta Huma se beneficiaría con políza de seguro de vida y accidentes que contrataría el Congreso. - Pedro Pablo Kuczynski y su socio Gerardo Sepúlveda pasaran a juicio público por Lava Jato. - Consejo Fiscal advierte optimismo excesivo del MEF en su proyección económica del Perú. - Ideeleradio se une a la campaña por la libertad de prensa en Gaza.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Lanzan cartucho de dinamita en casa de periodista en Huaral. - Nuevos ministros de Justicia, Midis y de la Mujer consignan expedientes judiciales en declaraciones juradas. - Presentan moción para que Eduardo Arana explique en el Congreso la designación de Juan José Santiváñez en el Minjus. - Dina Boluarte defiende compra de aeronaves para la Fuerza Aérea y sostiene que críticas en contra son “inaceptables e irresponsables”. - Fallo del TC favorece la devolución de inmuebles a sentenciados de la red del narcoterrorista ‘Artemio’. - Caso Árbitros de Odebrecht: Poder Judicial dictó 4 años de prisión contra Juan de Dios Zorrilla. - Municipalidad de Lima presentó segundo lote de trenes que serán almacenados en el Parque de la Muralla. - Miraflores: vecinos rechazan instalación de módulo de seguridad en parque. - Bettsy Chávez podría morir en 3 días si continúa con huelga de hambre seca, advierte médico del INPE. - Exclusiva: La defensa de Gino Ríos ante la JNJ.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Caso Saweto: ratifican 28 años de cárcel contra madereros por crimen de líderes indígenas. - Cancillería y MINJUSDH siguen evaluando el retiro del Perú de la Corte IDH, señala el premier. - Fernando Rospigliosi pide a la JNJ destituir a juez Richard Concepción Carhuancho por no aplicar ley que restringe lesa humanidad. - Investigan reunión entre Tomás Gálvez y Castillo Alva: fiscal denuncia reglaje y anuncia demanda contra Delia Espinoza. - Keiko Fujimori: TC evalúa hoy miércoles recurso que busca archivar Caso Cocteles. - Fiscalía allanó la vivienda de Nicanor Boluarte y otros involucrados en el caso Mina El Dorado. - Exclusiva: ¿Proselitismo político durante la semana de representación?

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Juan José Santiváñez es el nuevo ministro de Justicia en remplazo de Enrique Alcántara. - JNJ declara desierto concurso para fiscal supremo: ningún candidato aprobó la tercera etapa. - Ya no se podrá solicitar información sobre vehículos oficiales: PCM lo declara de carácter reservado. - Congreso: subcomisión acata fallo del TC y congela denuncias constitucionales contra Dina Boluarte hasta 2026. - Defensoría del Pueblo buscó blindar a Dina Boluarte evitando que sea investigada por delitos de corrupción. - Dina Boluarte busca blindaje total: pide al TC que la Fiscalía solo pueda solicitarle información una vez. - Denuncian que especialistas del Hospital de la PNP atienden en Palacio mientras pacientes esperan varios meses por citas. - Investigan al juez Concepción Carhuancho por ordenar prisión preventiva contra Mateo Castañeda. - Exclusiva: Alimentos en mal estado en Cuna Más.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Aidesep advierte graves daños en causes de Rios Pachiteam Yuyapichis y Aguaytía debido a la minería ilegal. - Trabajadores agroindustriales se movilizarán el jueves 21 exigiendo que el Gobierno no promulgue la Ley Chimper 2.0. - Convocan a un plantón en el Poder Judicial en contra de la Ley de Amnistía. - Corte IDH rechaza participación virtual del Estado peruano en el caso Barrios Altos y Cantuta. - Tribunal Constitucional suspende investigaciones a Dina Boluarte hasta que termine su mandato. - JNJ admite a trámite pedido de vacancia contra Gino Ríos por denuncia de violencia familiar. - Comisión de Alejandro Muñante apunta a una persecución política contra fiscales Lava Jato. - Tren Lima-Chosica: segundo lote de vagones llegará este sábado 23 de agosto, pero irá directo al depósito. - Exclusiva: El expediente Gino Ríos.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: - Dina Boluarte criticó en el 2022 el habeas corpus del TC a favor de Albeetro Fujimori. - Militares se niegan a pedir perdón a las víctimas del conflicto armado interno. - MP demandará la inconstitucionalidad de la Ley 32419 que concede amnistía a miembros de las FF. AA., PNP y otros. - Corte IDH analizará ampliación de medidas cautelares en los casos Barrios Altos y Cantuta, tras promulgacion de la Ley de Amnistía. - Exclusiva: La nueva directora general de la JNJ.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: - Ministerio del Interior compró 168 vehículos de lujo, pero quitó financiamiento a sueldos y pensiones de la PNP. - Efectivos investigados por tráfico ilícito de drogas trabajan en dependencias policiales. - Altos mandos policiales festejaron pese a aumento del número de homicidios en el país. - JNJ insiste en reponer a Patricia Benavides en la Fiscalía: da por cumplida suspensión de 60 días. - Delia Espinoza: Titular de la Fiscalía ofreció conferencia de prensa donde criticó fallos del PJ sobre Patricia Benavides y del TC sobre extensión de dominio. - Gustavo Gorriti responde a Alejandro Muñante tras citarlo a declarar al Congreso: "No concurriré a su viciada comisión". - Cinco alianzas políticas solicitaron su inscripción ante el JNE para las elecciones 2026. - Alejandro Cavero respalda candidatura de Phillip Butters y critica a Rafael López Aliaga. - Pleno del Congreso aprueba viaje de Dina Boluarte a Japón e Indonesia del 5 a 12 de agosto. - Exclusiva: La JNJ y las denuncias contra Fernández Jerí.

In this special episode of Dividend Talk, we tackle one of the most frustrating topics for European investors: dividend withholding tax. Our guest is Thomas Rappold, founder of Divizend.com, a platform built to automate and simplify dividend tax reclaims for retail investors. Thomas shares how his own investing struggles led him to build the company, and how Divizend is helping thousands of investors recover lost income from foreign dividends.We discuss:​What dividend withholding tax is (and why it's such a headache)​Why most investors miss out on reclaiming what's rightfully theirs​The upcoming EU-Faster regulation and digital tax residency certificates​The role of brokers, the EU Commission, and what's changing by 2028​Practical steps for reclaiming your foreign dividend taxes​Why dividend investors need to push for change and how Divizend is giving us a voice​Thomas also shares his unique investing mindset (yes, he owns both Palantir and Lindt!) and replaces a stock in our Dividend Growth Community Portfolio.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: - Denuncian ante la Fiscalía y el Congreso a la comisión que seleccionó a Gino Ríos como presidente de la JNJ. - Patricia Benavides: Poder Judicial anula la suspensión por 24 meses en contra de la exfiscal de la Nación. - Dina Boluarte contra los derechos humanos: presidenta ataca a la Corte IDH ante observaciones a ley de amnistía. - Advierten que proyecto del congresista Muñante sobre sanciones por denuncias falsas por violencia familiar afectaría a las víctimas. - Tribunal Constitucional elimina la extinción de dominio antes del 2018. - Patricia Benavides: Ministerio Público asegura que tesis de la suspendida exfiscal de la Nación cuenta con 85% de plagio. - Exclusiva: El apoyo del Congreso a Patricia Benavides para su retorno a la Fiscalía

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: - Josué Gutiérrez es pifiado y expulsado de evento en Puno. - Dina Boluarte y César Acuña también son rechazados como autoridades por la población. - JNJ abre investigación contra Delia Espinoza por presunta violación a la intimidad de Juan José Santiváñez. - Gino Ríos reaparece y desmerece sentencia de violencia familiar en su contra: “No hay delito". - Jorge Cuba condenado: Poder Judicial dicta 21 años y 8 meses a exviceministro de Alan García. - Se oficializó la lista 1 por la Mesa Directiva del Congreso: José Jerí, Fernando Rospigliosi, Waldemar Cerrón e Ilich López. - Congreso blinda a Rosío Torres por caso “Mochasueldos”. - Congreso aprueba proyecto de ley de crédito suplementario para darle más presupuesto a alcaldes y gobernadores. - César Sandoval envía carta notarial a Rafael López Aliaga por afirmaciones públicas: "Tiene 24 horas para rectificarse". - Exclusiva: La estrategia de Gino Ríos para evitar la vacancia de la JNJ.

Acuña fue abucheado en desfile y se burlaron de él por no saber multiplicar. Gino Ríos, presidente de la JNJ, admitió violencia familiar pero se niega a renunciar. Josué Gutiérrez "el ofensor del pueblo" fue repudiado en Puno por ser cómplice del gobierno.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: - La Corte IDH alertó 13 incumplimientos de sentencias durante el Gobierno de Boluarte. - Dina Boluarte es blindada nuevamente por el Congreso, SAC archiva denuncia constitucional por muertes en protestas. - Gino Ríos: presidente de la JNJ fue elegido pese a contar con sentencia firme por violencia familiar. - JNJ abre investigación preliminar a Delia Espinoza por no reponer a Patricia Benavides como fiscal de la nación. - PJ rechazó recurso de Patricia Benavides por excluir a la fiscal de la nación, Delia Espinoza, de investigaciones en su contra. - Alcaldes que visitaron la oficina de Juan José Santivañez se beneficiarán con un crédito suplementario sin acudir al MEF. - Revelan chat grupal entre Jorge Montero y mineros informales: apoyaba extensión del Reinfo. - Contraloría detectó que el último mantenimiento de los trenes Caltrain se realizó 18 años antes de lo informado por la MML. - César Acuña dice que le gustaba las matemáticas, pero no responde cuánto es 7x8. - Diversas organizaciones convocan a movilizaciones los días 23, 27, 28 y 29 de julio contra el gobierno de Dina Boluarte. - Exclusiva: Descontrol en Sucamec.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: - Ley APCI: sala excluye a abogados de ONG que defendían a «líderes indígenas» en Caso Baguazo. - CIDH realizó audiencia para analizar la ley aprobada por el Congreso contra las ONG. - Fiscalía solicita suspender por 18 meses a Víctor Zanabria de su cargo como comandante general PNP. - Congreso: solicitan vacancia de Gino Ríos como presidente de la JNJ por sentencia de violencia familiar. - Presidenta Boluarte invoca a una cruzada por la paz en Perú en homenaje a papa León XIV. - Malaver sobre asesinados por presuntos extorsionadores: "Habría que ver cómo fue llevada esa vida, a veces, están llevadas por el mal camino". - Eduardo Salhuana sobre sueldo de Dina Boluarte: “Es un tema que hay que ordenar, quizás no sea el momento”. - Exclusiva: Viajes en Palacio de Gobierno.

Nuevo escándalo llega en formato de audio y compromete al MEF, y titular de Energía y Minas chateaba activamente con mineros ilegales. Amenazan a periodista que mostró estado de trenes “donados”; y la JNJ la preside un sentenciado por maltrato familiar.

S&P Futures are flat to lower this morning as market await this morning PPI report. President Trump indicated that drug tariffs are likely by Aug 1st with tariffs on semis to follow shortly afterwards. President Trump to meet with leaders from Bahrain and Qatar today. TTD gains on its inclusion to the S&P500. On the earnings front, BAC & JNJ are higher after earnings releases, GS & MS to report this morning. Tomorrow morning, GE, ABT, PEP, CTAS, NVS will be reporting.

S&P Futures are positive this morning as market react to the latest trade developments. Nivida appears to have the green light to ship its H20 chip to China. President Trump indicates a wiliness to discuss tariff rates with the E.U. President Trump will be in Pennsylvania today and is expected announce a $70B investment in AI and Energy. Before the bell today is the June inflation data as the CPI data is due out. TTD gains on its inclusion to the S&P500. On the earnings front, JPM, BK & WFC are higher after earnings beats. Tomorrow morning, JNJ, BAC, MS & GS will be reporting.

Dale Smothers says it's a “powerful thing” that traders aren't running to the bond market for safety. “I believe this is all due to the optimism” around the America First agenda of the Trump administration. He thinks the S&P 500 will finish the year around 6,500, citing pent-up demand and $7T “on the sidelines.” He argues that the market is broadening beyond tech, “a very good thing,” and he would love to see “consumer discretionary climbing a little bit higher.” His picks include AMZN, AAPL, and JNJ.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Did you buy the dip? Do you know how to use the tools you have? Here are AI hacks to use! ⁠⁠⁠⁠⁠GET THE TRENDSPIDER SALE HERE BEFORE IT ENDS⁠⁠⁠⁠⁠Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Seeking Alpha Premium⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠:  with a 7-day free trial—save $30⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SAVE ON TRENDSPIDER - GET THE ANNUAL SUBSCRIPTION TO GET MY 4 HOUR ALGORITHM ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: -La #JNJ amenaza a #DeliaEspinoza con usar la “fuerza pública” si no repone a #PatriciaBenavides. - El #SecretarioGeneraldelaJNJ pone en conocimiento del #Congreso resolución en caso #PatriciaBenavides. - La #JuntadeFiscalesSupremos pide a la #JNJ precisar cómo se repondrá a #PatriciaBenavides si #DeliaEspinoza ya es #FiscaldelaNación. - La #JNJ convoca a una reunión entre #DeliaEspinoza y #PatriciaBenavides. - Admiten #amparo presentado por #DeliaEspinoza contra regreso de #PatriciaBenavides como #FiscaldelaNación: audiencia será el 8 de agosto. - La #FederaciónLatinoamericanadeFiscales respalda la permanencia de #DeliaEspinoza como #FiscaldelaNación. - Exclusiva: peruanos pagarán defensa legal de #JuanJoséSantiváñez en otro caso.

Aldo Vásquez, exmiembro de la JNJ , conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

Magistrado de la JNJ denuncia que la misma institución le hace reglaje y confirma TODAS las irregularidades cometidas para favorecer a Patricia Benavides. En Piura, un escolar le dio a Dina clases de cómo gobernar; Y pronto en Lima: los drones kamikazes.

Inés Tello, expresidenta de la JNJ, conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

La fiscal de la Nación, Delia Espinoza, presentó un hábeas corpus ante una posible detención, tras el intento de Patricia Benavides de tomar por la fuerza la Fiscalía con apoyo de la JNJ. El Gobierno toma partido y apoya el retorno de Benavides.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Eduardo Salhuana intenta justificar visitas de mineros informales: “El Congreso es una institución de puertas abiertas”. - Comisión de Ética recomienda investigar a Susel Paredes por uso de baños del Congreso por personas transexuales. - Pleno del Congreso abordará mociones de censura contra Gustavo Adrianzén el próximo miércoles 14 de mayo. - Fiscalía sobre extinción de dominio: “Se debilita lucha contra la corrupción, crimen organizado, lavado de activos y delitos medioambientales”. - ONU DD. HH. expresa su preocupación por modificaciones a la Ley Apci y la CIDH pide al Gobierno derogarlo. - Relatora de la ONU alerta sobre hostigamiento y amenazas contra la suspendida fiscal Marita Barreto. - Junta de Fiscales Supremos expresa su rechazo a promulgación de modificatoria de la extinción de dominio. - Congresista Jorge Montoya se burla del aniversario del Ministerio Público e insiste en vincular al IDL y a Gustavo Gorriti con dicha institución. - 'Cuchillo', sindicado por asesinato múltiple en Pataz, envió carta notarial a la presidenta Dina Boluarte. - Presidenta Dina Boluarte: sentamos las bases de un nuevo modelo económico que trae crecimiento y empleo. - Excongresista Cayo Galindo juró como nuevo integrante de la JNJ. - Exclusivo: Gobierno pretende eliminar 14 programas de infraestructura.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: - Dina Boluarte pide a la JNJ evaluar y sancionar a fiscales y jueces que liberan delincuentes. - Nuevo aeropuerto Jorge Chávez: colocan muros de dos metros en Av. Morales Duárez para “mejorar” la imagen de ingreso al terminal. - Fiscal de la Nación remueve a fiscal que investigaba muertes durante las protestas contra Dina Boluarte. - Asociación de familiares de desaparecidos critica leyes aprobadas por el Comgreso en materia de DDHH. - Amnistía Internacional: leyes aprobadas por el Congreso ponen al Perú en un "escenario de alto riesgo" para los DD.HH. - Fuerza Popular, Avanza País, APP y otros 28 partidos presentaron firmas falsas para inscribirse en elecciones, según Reniec. - Red de sobrevivientes del Perú rechaza la participación de Juan Luis Cipriani en las reuniones previas al cónclave por estar suspendido de sus funciones. - Eduardo Salhuana defiende permanencia de Yessenia Lozano. - Exclusivo: Las visitas a Yessenia Lozano.

So when Lauren invited Heather Campain, VP, CPG Integrated Go-to-Market Strategy at Epsilon, onto the podcast I immediately went to her LinkedIn, and here's what I saw below her name: Unified Commerce Leader | Silo Slayer | Possibilist | Omni Integration | eComm| Marketing | Retail Media | Joint Value Realization | JBP | Product Dev | Data+Analytics | Transformation. That plus 10 years at JnJ, Head of Strategy for the Walmart Business at Pepsico, and now at Epsilon. I thought “this is going to be good.” And it was.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: Papa Francisco, primer pontífice latinoamericano, fallece a los 88 años. Dina Boluarte vuelve a beneficiar a Wilfredo Oscorima: transfiere 49 millones de soles a obra que ya fue financiada. Juan José Santiváñez ganará más de S/17.000 mensuales a cargo de la nueva oficina del Despacho Presidencial. Caso Medifarma: suero mortal cobra su séptima víctima y Congreso no interpelará al ministro de Salud. -Minsa rechaza financiamiento del Banco Mundial y sale en defensa de funcionaria. Delia Espinoza envió a la JNJ denuncia de José Domingo Pérez contra Juan Fernández Jerí. Expreso y Alejandro Aguinaga atacan a fiscal José Domingo Pérez con supuesta enfermedad de salud mental. Susana Villarán: sala resuelve apelaciones que venían dilatando el inicio del juicio de la exalcadesa. Fiscalía no pudo verificar veracidad de audio contra Marita Barreto. Denuncian millonarias órdenes de servicios del Mininter en personal trainer para sus trabajadores, evento deportivo y más. Jorge Montoya usa caricatura sin firma para decir mentiras sobre 'Carlincaturas' de La República. Organismos internacionales expresan su preocupaciób por promulgación de la Ley Anti ONG. Exclusivo: El Congreso y cómo se gestó la Ley Anti ONG.

This week, Nathan from Dividend Watch joins us to discuss everything from high-yield strategies to sustainable yields, the psychology behind investor decisions, and even the impact of global tariffs. Plus, hear our thoughts on companies like Johnson & Johnson, Broadcom, and many more.Tickers mentioned: JNJ, AVGO, SCHD, VYM, AT&T, JEPQ, JPI, LVMH, ASML, NOVO, UN, SAP, IBM, BRBY, META, GOOG, MSFT, AAPL, SHEL, AGG, BTI.Site: https://dividend.watchLinkedIn: https://www.linkedin.com/in/nathan-hamilton-8492456/

S&P Futures are moving higher mainly due to optimism on tariff exemptions. The Trump tariff narrative remain the key focus as the White House indicates that that it is looking to help the auto sector. Pharma & semiconductor stocks are on watch as they are under review by the Trump tariff team. China has suspended jet deliveries from Boeing in retaliatory move. U.S. trade officials met with EU's trade representative yesterday, the demands from the Trump administration will be difficult for the Eurozone to agree to. Mining stocks are displaying gains due to a report that indicates President Trump has plans to stockpile critical metals to counter China. On the economic calendar today are reports on Import Exports prices and the Empire state Manufactuing index. JNJ, BACPNC & ERIC are higher after earnings announcements. Caterpillar named a new CEO.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: Murió Mario Vargas Llosa: el nobel de literatura dejó de existir a los 89 años en Lima. Subcomisión de Acusaciones Constitucionales archiva denuncia constitucional contra Dina Boluarte por caso Rólex. Subsistema Nacional Especializado en Extinción de Dominio advierte que 5 mil casos tendrían que archivarse con ley del Congreso. Lima y Callao se desangran: Matan 10 personas en menos de 24 horas. Gobierno prohíbe que motociclistas viajen con acompañante y amplía estado de emergencia en Lima y Callao. Autoridades del Estado firman acta de compromiso en materia de seguridad ciudadana realizado en el Congreso. Datum: El 79% cree que situación seguirá igual o peor con el nuevo ministro del Interior. Quedan 43 partidos habilitados para las elecciones generales del 2026. Alfonso López Chau renunció al cargo de rector de la UNI para iniciar su campaña presidencial. Alejandro Cavero ve con buenos ojos la candidatura de Phillip Butters a la presidencia por Avanza País. Exoperario de Medifarma rompe su silencio y asegura que lo incriminaron: “Me obligaron a firmar una carta”. Sociedad Civil cuestiona la Ley Anti ONG apronada por el Congreso. Exclusivo: Los procesos abiertos de Antonio Fernández Jerí en la JNJ.

US equities saw S&P 500 going down 0.33% and Nasdaq with modest gains as worries about 20% universal tariffs and stagflation concerns surrounding the ISM manufacturing print remained overhangs. Treasury yields were flat overnight, gold higher and crude lower. The dollar index was flat, Bitcoin futures were up 3.4%. The overall performance of Asian Equity market was directionless, with no major benchmark moving higher or lower by more than 0.5%, European equity markets opened lower, following broad strength on Tuesday. Companies mentioned: JNJ, Boeing, Andreesen Horowitz, Becton Dickinson, Qualcomm

S&P Futures are displaying weakness this morning as the markets continue to await clarity on the tariff situation. U.S. auto manufactures are making a push to exclude certain car components from tariffs. President Trump is expected to sign Executive Orders today related to national security and economic policy. There is a press conference today at noon. Key economic reports due out today on the ISM Manufacturing and JOLT's data. A Texas court rejected JNJ use of Chapter 11 for its talc cancer fund. PVH and PRGS are higher this morning after earnings releases.

Today, we share our five top stocks to buy if they won thelottery, including picks like Pernod Ricard, Visa, Ferrari, Microsoft, and LVMH. With no restrictions, such as yield, we look at key factors driving our choices, such as brand power, growth potential, and pricing strength.We also preview an upcoming newsletter on big pharma, with Derek focusing on Merck & Co. and the top-selling drug, Kuda.And as always, we finish with some excellent Listener questions

Hey everyone, and welcome back to Dividend Talk! In this episode, we look into the latest market corrections and explore exciting stock opportunities. We chat about Intel's new CEO, the football matches that had us on the edge of our seats, and some fantastic dividend announcements from companies like Legal and General and Henkel. Plus, we answer your insightful questions on portfolio strategy, handling market volatility, and killer criteria for your holdings. Tickers Mentioned: INTC, V, O, SHEL, ASR, EPI, MSFT, EVVTY, SBUX, PEP, V, LGEN, SPX, MMM, RHM, JNJ, XOM, TGT, HD, WMT, GLB, CILA, TRP, GOOG, ASML, BA, MUM.

The Olympics. The World Cup. The Super Bowl. These competitions bring the world together to back their favorite teams as they compete for the ultimate title. But March Market Cap Madness has an even bigger draw, because you not only get to root for your favorite; you get to compete! Strap in and get your pencils ready, it's go time! Companies discussed: DAVA, DUOL, GXO, UA, JNJ,  SMMT, AX, ROKU, DDOG, IOT, FICO Host: David Gardner Guests: Andy Cross, Matt Argersinger Producer: Rick Engdahl

Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).Show Notes:Psychedelic Stocks: Focus On Their CashDeep Dive: Atai Life SciencesFDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedRead our episode transcriptsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Policía separó solo por inasistencias a suboficial investigado por muerte en protestas. - Dina Boluarte envía carta notarial a la Clínica Sanna para evitar que entreguen su historial clínico a la Fiscalía. - Adrianzén dice que colapso del Puente Chancay era previsible por su antigüedad. - JNJ confirma apertura de procedimiento disciplinario contra Janet Tello y 4 jueces supremos y asegura respeto al debido proceso. - Janet Tello califica de apresurado el proceso disciplinario en su contra en la JNJ. - Millonario buffet en el Congreso: nuevo contrato de alimentos costará 1.6 millones de soles. - Alejandro Muñante y Fernando Rospigliosi piden que Cancillería solicite información al gobierno de EE. UU. sobre financiamiento de Usaid en el Perú. - Rafael López Aliaga admite que no podrá cumplir su promesa de adquirir 10 mil motos para Lima. - Exclusiva: Mateo Castañeda y la municipalidad de Comas.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Niños le recuerdan a Dina Boluarte el caso Rolex y los almuerzos a 10 soles durante Carnaval Ayacuchano. - Rafael Dumett: Hay una guerra declarada por fuerzas autoritarias aliadas con intereses corruptos. - Rafael López Aliaga admite que si votó a favor de otorgarle peajes a OAS en 2009. - Janet Tello, presidenta del Poder Judicial, califica como “preocupante” que JNJ le abra proceso disciplinario. - JNJ admite denuncia contra Delia Espinoza interpuesta por Juan José Santiváñez. - Dina Boluarte seguirá siendo investigada por el Caso ‘Cofre’: PJ rechaza recurso de la presidenta. - Javier González Olaechea quiere ser presidente e invitar a Elon Musk al Perú. - Trump suspende una ley que prohíbe el soborno por parte de funcionarios extranjeros. - Exclusiva 1: Rafael López Aliaga y los pagos a su asesor. - Exclusiva 2: Más prohibiciones para postular al Congreso.

This week Russ talks with Dr. Robert Ramsey who runs the Facebook group Dentistry Gone Wild which offers a humorous non-political take on dentistry that we all often need in the world of dental facebook.  We talk for the hour about Robert's journey from JnJ to dentistry, and why we both left Corporate America to go do dentistry.  Robert talks about the DSOs he works for and his experience doing HMO dentistry (spoiler alert: it isn't all that bad).  Finally we discuss refunds and specialists.  

In this episode, we explore where value might be hiding in today's high-valuation market. From overlooked oil and gas plays to global opportunities in Japanese railways and Chinese big tech, we break down areas of potential interest for savvy investors. We also discuss the pitfalls and potential in pharma, defense, and precious metal miners, as well as the challenges pandemic darlings face in a post-COVID world. Plus, Braden dives into the concept of quality in investing, inspired by Dev Kantesaria of Valley Forge Capital. Discover why the intersection of growth and predictability defines great companies and how this framework can help you identify enduring opportunities in any market environment. Tickers of Stocks/ETFs discussed: HAL, TVK.TO, CNQ.TO, TOU.TO, ENB.TO, TRP.TO, KMI, MPC, JNJ, PFE, MRK, LLY, NVO, KVUE,PPH, IHE, ZHU.TO, LMT, UNP, 9020, KWEB, BABA, FNV.TO, WPM.TO, ABX.TO, NGT.TO, GDX, GDXJ, ZGD.TO, DOO.TO, 7309 Check out our portfolio by going to Jointci.com Our Website Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Finchat.io for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

Join the European Dividend Growth Investor (EDGI) and Derek as we dive into the latest financial news and dividend company earnings. In this episode, we analyse Signify's dividend hike, Johnson & Johnson's earnings, and Texas Instruments' financial struggles. We also talk about topics like the "Income Factory" investment strategy, currency diversification, and the risks of covered call ETFs. Finally, EDGI shared highlights from the Utrecht Dividend Day Mentioned Tickers:PHG, JNJ, PG, UL, TXN, QCOM, NKE

S&P Futures are moving higher this morning with positive momentum in tech stocks. The tech rally is due to a White House announcement on the Stargate Project which is $500B fund to build out AI infrastructure. Concerns over tariffs are falling, while Trump has spoken about plans to impose 25% tariffs on Feb 1 on goods from Mexico & Canada, the trade deficit study is schedule for April 1st. Earnings are also in focus today with NFLX, IBKR & JNJ moving higher after releasing their reports. European shares are showing gains & oil prices are higher by +0.25% this morning.

S&P Futures are trading higher as the market react to a new administration in the White House. The President's ability to issue Executive Orders will be on watch this week with possible tariff announcement on Canada and Mexico. Earning reports will be in focus this week ahead as a host of major companies are scheduled to release. MMM reported a beat this morning and after the bell today NFLX, STX & UAL will report. Tomorrow morning, PG, JNJ, ABT, TRV & HAL will be releasing earnings reports. Davos conference is underway, President Trump is expected to remotely address the forum on Thursday. European shares are starting to pull back & oil prices are down more than -1.5% this morning.

In this episode of Dividend Talk, we dive into the world of dividend-focused ETFs available to European investors. In the News of the Week, we explore the recent sharp decline in Greggs' share price following its trading update, despite record sales. Is this an opportunity to buy, or should investors look elsewhere? The Listener Questions segment tackles a range of intriguing topics: How to prioritise investments when building a dividend portfolio. Why many REITs show negative ROIC vs WACC differences. Expectations for organic growth in diversified dividend portfolios. A thought experiment involving a €50,000 inheritance and turnaround companies. Finally, we wrap up with stock-specific discussions, including Schneider Electric, PepsiCo, and Eaton, while addressing questions on private equity, T. Rowe Price, and Sonoco Products.

These violent delights have violent ends. Between 1992 BCE and 1941 BCE, King Montu-Hotep (“Montu is Content”) ruled the southern kingdom. And he led efforts to expand Theban power, and ultimately reunify the Two Lands… Logo image: Montu, in a chapel of Ramesses III at Karnak (Kairoinfo4u). Website: www.egyptianhistorypodcast.com. Support the show via Patreon www.patreon.com/egyptpodcast. Make a one-time donation via PayPal payments. Music and interludes by Keith Zizza www.keithzizza.net. Music and interludes by Luke Chaos www.chaosmusick.com. Montuhotep's Expansion into Wawat / Nubia and the records of the wars: Darnell, ‘The Route of the Eleventh Dynasty Expansion into Nubia: An Interpretation Based on the Rock Inscriptions of Tjehemau at Abisko', Zeitschrift für Ägyptische Sprache und Altertumskunde 131 (2004), 23—37. Available on Academia.edu. Darnell, ‘The Eleventh Dynasty Royal Inscription from Deir el-Ballas', Revue d'Égyptologie 59 (2008), 81—110. Available on Academia.edu. Montuhotep's Mahat Chapel at Abydos, discovered in 2014: Josef Wegner at Academia.edu and Damarany in Abydos: The Sacred Land (2019), JSTOR. Scholarly debates on the timeline and events of the Reunification: Brovarski, ‘The Hare and Oryx Nomes in the First Intermediate Period and Early Middle Kingdom', in Egyptian Culture and Society: Studies in Honour of Naguib Kanawati, 1 (2010), 31—85. Available on Academia.edu. This was the study I followed in my reconstruction. Willems, ‘The Nomarchs of the Hare Nome and Early Middle Kingdom History', Jaarbericht van het Vooraziatisch-Egyptisch Genootschap Ex Oriente Lux 28 (1985), 80—102. Available at Researchgate. Nubia – The Archaeology of Wawat and Kerma: Kerma – Mission archéologique suisse à Kerma (Soudan) C. Bonnet, ‘The Cities of Kerma and Pnubs-Dokki Gel', in G. Emberling and B. B. Williams (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2021), 201—212. H. Hafsaas, ‘The C-Group People in Lower Nubia: Cattle Pastoralists on the Frontier Between Egypt and Kush', in B. B. Williams and G. Emberling (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2020), 157—177. G. K. Meurer, ‘Nubians in Egypt from the Early Dynastic Period to the New Kingdom', in B. B. Williams and G. Emberling (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2020), 289—308. B. B. Williams, ‘Kush in the Wider World During the Kerma Period', in G. Emberling and B. B. Williams (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2021), 179--200. The Tomb of General Antef, with images of siege towers and naval forces: B. Jaroš-Deckert, Grabung im Asasif. 1963-1970. Band 5: das Grab des Jnj-jtj.f. Die Wandmalereien der 11. Dynastie, 12 (1984). Learn more about your ad choices. Visit megaphone.fm/adchoices